

C-Bond Systems' EPA-Registered MB-10 Tablets Provide Effective Disinfection from SARS-CoV-2, the Virus that Causes COVID-19

With its exclusive rights to sell into the transportation sector, the Company is helping businesses protect their customers with MB-10 Tablets, a broad spectrum disinfectant effective against a wide range of bacteria and viruses

HOUSTON, Dec. 03, 2020 (GLOBE NEWSWIRE) -- <u>C-Bond Systems</u>' (the "Company" or "C-Bond") (OTC: CBNT) EPA-registered MB-10 Tablets provide an effective means of disinfection from a wide range of bacteria and viruses, including SARS-CoV-2, the virus that causes COVID-19.

The <u>Centers for Disease Control and Prevention</u> reports that since January 21, 2020, there have been 13,447,627 cases of COVID-19 in the U.S. alone, and 267,302 deaths as of December 1, 2020. While new vaccine candidates appear to be close to FDA approval, the way businesses and consumers clean and disinfect their facilities and homes is likely changed for years to come.

The <u>EPA</u> recommends disinfection using EPA-approved disinfectants against COVID-19 to help reduce the risk of spreading or developing COVID-19. According to the EPA, "Frequent disinfection of surfaces and objects touched by multiple people is important. By killing germs on a surface after cleaning, you can further lower the risk of spreading infection. EPA-approved disinfectants are an important part of reducing the risk of exposure to COVID-19."

MB-10 Chlorine Dioxide Tablets are listed on EPA's List N (EPA #: 70060-19-46269) with an Emerging Viral Pathogen claim and are featured on the Center for Biocide Chemistries' list of Novel Coronavirus (COVID-19)—Fighting Products.

C-Bond has exclusive rights to sell MB-10 Tablets within the verticals it serves, namely transportation. That includes automotive distributors, rental car companies, fleets, public transportation, ride sharing, and more. The Company is also selling MB-10 Tablets through international distribution partners.

MB-10 Tablets are effective for hard, non-porous surfaces such as glass, plastics, sealed fiberglass, consoles, A/C, door handles, seating and seat belts, LED/LCD screens and electronics, and a wide range of metals materials, without leaving a residue or odor. MB-10 Tablets also protect without staining or discoloring. Easy to apply using a commercially

available sprayer, MB-10 effectively disinfects in minutes and provides fast-acting protection that is safe for skin contact. The tablets are also gentle on the environment, breaking down harmlessly soon after the disinfection application.

"C-Bond is determined to help in the fight against this virus and we believe MB-10 Tablets offer the best option for disinfecting hard, non-porous surfaces whether in/on a vehicle or facility against the spread of COVID-19," stated Scott R. Silverman, Chairman and CEO of C-Bond. "MB-10 Tablets have many advantages over competing products ranging from low cost of shipping to zero cytotoxicity, offering a proven way to safely and thoroughly disinfect."

For more information about MB-10 Tablets or to place an order, please contact C-Bond Systems at 832-649-5658 or toll-free at 844-602-2663. Additional information can also be found on the Company's website at https://cbondsystems.com/mb-10-tablets/.

About C-Bond

C-Bond Systems, Inc. (OTC: CBNT) is a Houston-based advanced nanotechnology company and marketer of the patented C-Bond technology, developed in conjunction with Rice University and independently proven to significantly strengthen glass in key automotive and structural applications. The Company's Transportation Solutions Group sells C-Bond nanoShield, a liquid solution applied directly to automotive windshields, sold through distributors. The Company's Safety Solutions Group sells ballistic-resistant glass solutions and FN NANO Coating directly to private enterprises, schools, hospitals and government agencies. For more information, please visit our website: www.cbondsystems.com/cbondsys/ and Twitter: https://twitter.com/CBond Systems.

Forward-Looking Statements

Statements in this press release about our future expectations constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, C-Bond's ability to raise capital; the Company's ability to successfully commercialize its products; the effect of the COVID-19 global pandemic on the Company's ability to operate; as well as other risks. Additional information about these and other factors may be described in the Company's filings with the Securities and Exchange Commission ("SEC") including its Form 10-K filed on March 25, 2020, its Forms 10-Q filed on November 16, 2020, August 14, 2020, and May 15, 2020, and in future filings with the SEC. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

Contact:

Allison Tomek C-Bond Systems 6035 South Loop East Houston, TX 77033 atomek@cbondsystems.com

Brokers and Analysts: Chesapeake Group 410-825-3930 info@chesapeakegp.com



Source: C-Bond Systems